Longfei Wu

Longfei Wu

Auto-generated profile, based on publicly available information

Longfei Wu

Department of Neurology, Xuanwu Hospital, Capital Medical University, China

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2018 in Journal of Neuroinflammation
Verified
Journal Article
Open access
PDF file
LWLiyan Wang
Liyan Wang
JDJiangang Duan
Jiangang Duan
TBTingting Bian
Tingting Bian
RMRan Meng
Ran Meng
LWLongfei Wu
Longfei Wu
Xunming JiXunming Ji
Xunming Ji
Few studies have suggested a relationship between inflammation and cerebral venous thrombosis (CVT). This retrospective study aimed to explore the changes in inflammation in different CVT stages and the correlation between inflammation and severity and outcome of CVT. In total, 95 suitable patients with CVT and 41 controls were compared. Patients with CVT were divided into three groups. The inflammatory factors studied included hypersensitive C-reactive protein (Hs-CRP), interleukin-6 (IL-6), and neutrophil-to-lymphocyte ratio (NLR) in the peripheral blood and immunoglobulin A (IgA), immunoglobulin M (IgM), and immunoglobulin G (IgG) in the cerebrospinal fluid (CSF). The severity of CVT was evaluated with the modified Rankin Scale (mRS), the National Institutes of Health Stroke Scale (NIHSS), fundus condition, intracranial pressure (ICP), and complications on admission. The short-term outcome was evaluated with the mRS at discharge. The following results were obtained: (1) Inflammatory factor levels in patients with CVT were higher than those in the controls. (2) Inflammatory factor levels in the acute and subacute stages were significantly higher than those in the chronic stage (all P < 0.05). (3) Serum NLR and CSF IgM levels were positively related to baseline degree of disability (odds ratio [OR], 1.279, 95% confidence interval [CI] 1.009–1.621, P = 0.042; OR 1.402, 95% CI 1.036–1.896, P = 0.028). The Hs-CRP level was positively correlated with the baseline occurrence of seizure (OR 1.040, 95% CI 1.001–1.080, P = 0.043). The baseline serum NLR (r = 0.244, P = 0.017), CSF IgA (r = 0.615, P < 0.001), CSF IgM (r = 0.752, P < 0.001), and CSF IgG (r = 0.248, P = 0.015) levels were positively associated with NIHSS. (4) The baseline NLR was significantly associated with high risk of poor outcome at discharge (OR 1.339, 95% CI 1.097–1.784, P = 0.007). Moreover, the ROC showed that NLR ≥ 4.205 could better predict the poor outcome at discharge. The data were analyzed using SPSS. Inflammation may develop after CVT and gradually decrease during the course. Inflammation was significantly correlated with severity on admission and short-term poor outcome at discharge in CVT.

20 January 2026 in American Journal of Cardiovascular Drugs
Verified
Journal Article
Closed access
PDF file
JWJing Wang
Jing Wang
YQYue Qiao
Yue Qiao
SLSijie Li
Sijie Li
CLChuanhui Li
Chuanhui Li
CWChuanjie Wu
Chuanjie Wu
WZWenbo Zhao
Wenbo Zhao

15 April 2026 in Frontiers in Neurology
Verified
Journal Article
Open access
PDF file
SWShengjun Wang
Shengjun Wang
QMQingfeng Ma
Qingfeng Ma
XJXunming Ji
Xunming Ji
WZWenbo Zhao
Wenbo Zhao
LWLongfei Wu
Longfei Wu
Background: Previous evidence supports the efficacy and safety of intravenous urokinase thrombolysis in acute ischemic stroke (AIS), with additional advantages in terms of cost-effectiveness. Existing studies suggest that treatment response may be dose-dependent; however, current dosing practices remain largely empirical and lack standardization based on high-quality evidence. Establishing a weight-based dosing regimen is, therefore, essential to maximize therapeutic benefit and minimize risks. Objective: To determine the maximum tolerated dose (MTD) of urokinase and to develop an optimized weight-adjusted dosing protocol for AIS. Methods: OUTSET is a prospective, single-center, phase I, dose-escalation clinical trial using a weight-based, rolling-six design in patients with AIS. Patients who meet the inclusion criteria will be assigned to one of four dose groups (15,000 IU/kg, 20,000 IU/kg, 25,000 IU/kg and 30,000 IU/kg). Urokinase will be administered intravenously, diluted in 100 mL of normal saline, over a period of 30 min. Outcomes: The primary endpoint is the identification of the MTD based on dose-limiting toxicity events, including symptomatic intracranial hemorrhage, major bleeding, and other significant adverse events. Discussion: This study offers a structured, weight-based approach to determining the MTD of intravenous urokinase for AIS using a rolling-six dose-escalation design. By addressing the current lack of standardized, body-weight–adjusted dosing protocols, the findings may enhance the clinical safety and efficacy of urokinase thrombolysis. The results are expected to inform future phase II/III trials and support the development of individualized thrombolytic strategies in routine stroke care. Clinical trial registration: ClinicalTrials.gov identifier: NCT07047326.

2 February 2026 in CNS Drugs
Verified
Journal Article
Closed access
PDF file
JWJing Wang
Jing Wang
SLSijie Li
Sijie Li
QMQingfeng Ma
Qingfeng Ma
XJXunming Ji
Xunming Ji
LWLongfei Wu
Longfei Wu
WZWenbo Zhao
Wenbo Zhao